Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARRY-438162, MEK inhibitor · 2 trials · 4 indications
The ACR (American College of Rheumatology) Criteria is a standard criteria to measure the effectiveness of various arthritis medications or treatments in clinical trials for Rheumatoid Arthritis. The ACR 20 has a positive outcome if 20% improvement in tender or swollen joint counts were achieved as well as a 20% improvement in at least three of the other five criteria.
| Arm | Type | Description |
|---|---|---|
| ARRY-438162 (Schedule 1) | EXPERIMENTAL | - |
| ARRY-438162 (Schedule 2) | EXPERIMENTAL | - |
| ARRY-438162 (Schedule 3) | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| ARRY-438162 (MEK 162) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ARRY-438162, MEK inhibitor; oral | DRUG | multiple dose, single schedule |
| Placebo; oral | DRUG | matching placebo |
| ARRY-438162 (MEK162), MEK inhibitor; oral | DRUG | Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule. |
Key Inclusion Criteria: * Diagnosis of rheumatoid arthritis, based on the American College of Rheumatology (ACR) 1987 Revised Criteria, prior to first dose of study drug. * Patient has received a stable dose of methotrexate for ≥ 6 weeks prior to first dose of study drug and is willing to continue ...
Top 20 of 28 competitors
ARRY-438162 is an investigational small molecule MEK inhibitor being studied for the treatment of rheumatoid arthritis and advanced solid tumors. It has been evaluated in clinical trials for these conditions, though it remains in clinical development and is not approved by regulatory authorities.
ARRY-438162 targets MEK, a kinase enzyme involved in cell signaling pathways that regulate cell growth and division. By inhibiting MEK, the drug aims to disrupt signaling that can drive inflammation and tumor growth, which is why it is being studied in rheumatoid arthritis and advanced solid tumors.
Pfizer, Inc. (NYSE: PFE) is the developer of ARRY-438162. The company has sponsored clinical trials of the drug in patients with rheumatoid arthritis and advanced solid tumors.
ARRY-438162 has completed Phase 1 and Phase 2 clinical trials. The most advanced completed trial was a Phase 2 study in rheumatoid arthritis, while a Phase 1 study evaluated the drug in advanced solid tumors. The drug is investigational and not approved.
ARRY-438162 has been studied in two completed trials: NCT00650767, a Phase 2 study in rheumatoid arthritis with 201 participants, and NCT00959127, a Phase 1 study in advanced solid tumors with 93 participants. Both trials are completed, and no active trials are listed.
Yes, ARRY-438162 is also known as MEK162. The Phase 1 trial in advanced solid tumors, NCT00959127, refers to the drug as ARRY-438162 (MEK162), confirming that these names refer to the same investigational MEK inhibitor.